July 6, 2020 / 11:12 AM / a month ago

Regeneron begins COVID-19 antibody cocktail late-stage trial

July 6 (Reuters) - Regeneron Pharmaceuticals Inc said on Monday it began late-stage clinical trials to assess the effectiveness of its antibody cocktail in preventing and treating COVID-19.

The trial, run jointly with the National Institute of Allergy and Infectious Diseases, would test the therapy's ability to prevent infection in those who have had close exposure to a COVID-19 patient. (reut.rs/2O1ra93) (Reporting by Saumya Sibi Joseph in Bengaluru; Editing by Shinjini Ganguli)

0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below